302 related articles for article (PubMed ID: 21255410)
1. The immunoregulatory mechanisms of carcinoma for its survival and development.
Du C; Wang Y
J Exp Clin Cancer Res; 2011 Jan; 30(1):12. PubMed ID: 21255410
[TBL] [Abstract][Full Text] [Related]
2. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO.
Mondanelli G; Ugel S; Grohmann U; Bronte V
Curr Opin Pharmacol; 2017 Aug; 35():30-39. PubMed ID: 28554057
[TBL] [Abstract][Full Text] [Related]
3. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Sørensen RB; Hadrup SR; Svane IM; Hjortsø MC; Thor Straten P; Andersen MH
Blood; 2011 Feb; 117(7):2200-10. PubMed ID: 21079151
[TBL] [Abstract][Full Text] [Related]
8. IL-35Ig-expressing dendritic cells induce tolerance via Arginase 1.
Panfili E; Mondanelli G; Orabona C; Bianchi R; Gargaro M; Fallarino F; Puccetti P; Grohmann U; Volpi C; Belladonna ML
J Cell Mol Med; 2019 May; 23(5):3757-3761. PubMed ID: 30793469
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
13. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
14. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
15. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
16. IDO: a crossroads of immunology and physiology?
Entrican G
J Reprod Immunol; 2004 Apr; 61(2):63-5. PubMed ID: 15063629
[No Abstract] [Full Text] [Related]
17. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
18. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
19. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death.
Friedlein G; El Hage F; Vergnon I; Richon C; Saulnier P; Lécluse Y; Caignard A; Boumsell L; Bismuth G; Chouaib S; Mami-Chouaib F
J Immunol; 2007 Jun; 178(11):6821-7. PubMed ID: 17513730
[TBL] [Abstract][Full Text] [Related]
20. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
